Generation of mouse models of myeloid malignancy with combinatorial genetic lesions using CRISPR-Cas9 genome editing

A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity

Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116 · see citing works

Multiplex Genome Engineering Using CRISPR/Cas Systems

Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339 · see citing works

RNA-Guided Human Genome Engineering via Cas9

Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210 · see citing works

Genome-scale CRISPR-Cas9 knockout screening in human cells

Shalem, O., Sanjana, N. E., Hartenian, E., Shi, X., Scott, D. A., Mikkelsen, T. S., Heckl, D., Ebert, B. L., Root, D. E., Doench, J. G., et al. (2014) · Science · doi:10.1126/science.1247005 · Cited by 5,234 · see citing works

Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia

The Cancer Genome Atlas Research Network (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1301689 · Cited by 5,078 · see citing works

DNA targeting specificity of RNA-guided Cas9 nucleases

Hsu, P. D., Scott, D. A., Weinstein, J. A., Ran, F. A., Konermann, S., Agarwala, V., Li, Y., Fine, E. J., Wu, X., Shalem, O., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2647 · Cited by 4,741 · see citing works

One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering

Wang, H., Yang, H., Shivalila, C. S., Dawlaty, M. M., Cheng, A. W., Zhang, F., & Jaenisch, R. (2013) · Cell · doi:10.1016/j.cell.2013.04.025 · Cited by 3,495 · see citing works

High-Frequency off-Target Mutagenesis Induced by CRISPR-Cas Nucleases in Human Cells

Fu, Y., Foden, J. A., Khayter, C., Maeder, M. L., Reyon, D., Joung, J. K., & Sander, J. D. (2013) · Nature Biotechnology · doi:10.1038/nbt.2623 · Cited by 3,292 · see citing works

Efficient genome editing in zebrafish using a CRISPR-Cas system

Hwang, W. Y., Fu, Y., Reyon, D., Maeder, M. L., Tsai, S. Q., Sander, J. D., Peterson, R. T., Yeh, J.-R. J., & Joung, J. K. (2013) · Nature Biotechnology · doi:10.1038/nbt.2501 · Cited by 2,937 · see citing works

Genetic screens in human cells using the CRISPR-Cas9 system

Wang, T., Wei, J. J., Sabatini, D. M., & Lander, E. S. (2014) · Science · doi:10.1126/science.1246981 · Cited by 2,856 · see citing works

Targeted genome modification of crop plants using a CRISPR-Cas system

Shan, Q., Wang, Y., Li, J., Zhang, Y., Chen, K., Liang, Z., Zhang, K., Liu, J., Xi, J., Qiu, J., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2650 · Cited by 1,965 · see citing works

High Cleavage Efficiency of a 2A Peptide Derived from Porcine Teschovirus-1 in Human Cell Lines, Zebrafish and Mice

Kim, J. H., Lee, S. R., Li, L.-H., Park, H., Park, J.-H., Lee, K. Y., Kim, M., Shin, B. A., & Choi, S. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018556 · Cited by 1,340 · see citing works

Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation

Moran-Crusio, K., Reavie, L., Shih, A., Abdel-Wahab, O., Ndiaye-Lobry, D., Lobry, C., Figueroa, M. E., Vasanthakumar, A., Patel, J., Zhao, X., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.06.001 · Cited by 1,339 · see citing works

FLASH assembly of TALENs for high-throughput genome editing

Reyon, D., Tsai, S. Q., Khayter, C., Foden, J. A., Sander, J. D., & Joung, J. K. (2012) · Nature Biotechnology · doi:10.1038/nbt.2170 · Cited by 1,171 · see citing works

Dnmt3a is essential for hematopoietic stem cell differentiation

Challen, G. A., Sun, D., Jeong, M., Luo, M., Jelinek, J., Berg, J. S., Bock, C., Vasanthakumar, A., Gu, H., Xi, Y., et al. (2012) · Nature Genetics · doi:10.1038/ng.1009 · Cited by 1,122 · see citing works

TET2 Inactivation Results in Pleiotropic Hematopoietic Abnormalities in Mouse and Is a Recurrent Event during Human Lymphomagenesis

Quivoron, C., Couronné, L., Della Valle, V., Lopez, C. K., Plo, I., Wagner-Ballon, O., Do Cruzeiro, M., Delhommeau, F., Arnulf, B., Stern, M.-H., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.06.003 · Cited by 924 · see citing works

Heritable genome editing in C. elegans via a CRISPR-Cas9 system

Friedland, A. E., Tzur, Y. B., Esvelt, K. M., Colaiácovo, M. P., Church, G. M., & Calarco, J. A. (2013) · Nature Methods · doi:10.1038/nmeth.2532 · Cited by 899 · see citing works

Targeted Genome Editing Across Species Using ZFNs and TALENs

Wood, A. J., Lo, T., Zeitler, B., Pickle, C. S., Ralston, E. J., Lee, A. H., Amora, R., Miller, J. C., Leung, E., Meng, X., et al. (2011) · Science · doi:10.1126/science.1207773 · Cited by 664 · see citing works

Murine Leukemia Induced by Retroviral Gene Marking

Li, Z., Düllmann, J., Schiedlmeier, B., Schmidt, M., Kalle, C. V., Meyer, J., Forster, M., Stocking, C., Wahlers, A., Frank, O., et al. (2002) · Science · doi:10.1126/science.1068893 · Cited by 653 · see citing works

Targeted gene disruption in somatic zebrafish cells using engineered TALENs

Sander, J. D., Cade, L., Khayter, C., Reyon, D., Peterson, R. T., Joung, J. K., & Yeh, J.-R. J. (2011) · Nature Biotechnology · doi:10.1038/nbt.1934 · Cited by 622 · see citing works

G ENETICS OF M YELOID L EUKEMIAS

Kelly, L. M., & Gilliland, D. G. (2002) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev.genom.3.032802.115046 · Cited by 522 · see citing works

An Oncogenomics-Based In Vivo RNAi Screen Identifies Tumor Suppressors in Liver Cancer

Zender, L., Xue, W., Zuber, J. A., Semighini, C. P., Krasnitz, A., Ma, B., Zender, P., Kubicka, S., Luk, J. M., Schirmacher, P., et al. (2008) · Cell · doi:10.1016/j.cell.2008.09.061 · Cited by 425 · see citing works

Physiological Promoters Reduce the Genotoxic Risk of Integrating Gene Vectors

Zychlinski, D., Schambach, A., Modlich, U., Maetzig, T., Meyer, J., Grassman, E., Mishra, A., & Baum, C. (2008) · Molecular Therapy · doi:10.1038/mt.2008.5 · Cited by 271 · see citing works

FLT3 Mutations Confer Enhanced Proliferation and Survival Properties to Multipotent Progenitors in a Murine Model of Chronic Myelomonocytic Leukemia

Lee, B. H., Tóthová, Z., Levine, R. L., Anderson, K., Buza-Vidas, N., Cullen, D. E., McDowell, E. P., Adelsperger, J., Fröhling, S., Huntly, B. J. P., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.08.031 · Cited by 228 · see citing works

Ezh2 augments leukemogenicity by reinforcing differentiation blockage in acute myeloid leukemia.

Tanaka, S., Miyagi, S., Sashida, G., Chiba, T., Yuan, J., Mochizuki-Kashio, M., Suzuki, Y., Sugano, S., Nakaseko, C., Yokote, K., et al. (2012) · Blood · doi:10.1182/blood-2011-11-394932 · Cited by 201 · see citing works

Equal potency of gammaretroviral and lentiviral SIN vectors for expression of O6-methylguanine–DNA methyltransferase in hematopoietic cells

Schambach, A., Bohne, J., Chandra, S., Will, E., Margison, G. P., Williams, D. A., & Baum, C. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.08.012 · Cited by 197 · see citing works

Far-Red Fluorescent Protein Excitable with Red Lasers for Flow Cytometry and Superresolution STED Nanoscopy

Morozova, K. S., Piatkevich, K. D., Gould, T. J., Zhang, J., Bewersdorf, J., & Verkhusha, V. V. (2010) · Biophysical Journal · doi:10.1016/j.bpj.2010.04.025 · Cited by 159 · see citing works

A tumour suppressor network relying on the polyamine–hypusine axis

Scuoppo, C., Miething, C., Lindqvist, L., Reyes, J., Ruse, C. I., Appelmann, I., Yoon, S. C., Krasnitz, A., Teruya‐Feldstein, J., Pappin, D., et al. (2012) · Nature · doi:10.1038/nature11126 · Cited by 141 · see citing works

Quantitative effects of Nf1 inactivation on in vivo hematopoiesis

Zhang, Y., Taylor, B. R., Shannon, K., & Clapp, D. W. (2001) · Journal of Clinical Investigation · doi:10.1172/jci12758 · Cited by 54 · see citing works

FLT3-ITDs Instruct a Myeloid Differentiation and Transformation Bias in Lymphomyeloid Multipotent Progenitors

Mead, A. J., Kharazi, S., Atkinson, D., Macaulay, I. C., Pecquet, C., Loughran, S. J., Lutteropp, M., Woll, P. S., Chowdhury, O., Luc, S., et al. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.04.031 · Cited by 44 · see citing works

The new frontier of genome engineering with CRISPR-Cas9

Doudna, J. A., & Charpentier, E. (2014) · Science · doi:10.1126/science.1258096 · Cited by 7,062 · see citing works

Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects

Li, H., Yang, Y., Hong, W., Huang, M., Wu, M., & Zhao, X. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0089-y · Cited by 1,771 · see citing works

Delivering CRISPR: a review of the challenges and approaches

Lino, C. A., Harper, J. C., Carney, J. P., & Timlin, J. A. (2018) · Drug Delivery · doi:10.1080/10717544.2018.1474964 · Cited by 1,185 · see citing works

Modeling colorectal cancer using CRISPR-Cas9–mediated engineering of human intestinal organoids

Matano, M., Date, S., Shimokawa, M., Takano, A., Fujii, M., Ohta, Y., Watanabe, T., Kanai, T., & Sato, T. (2015) · Nature Medicine · doi:10.1038/nm.3802 · Cited by 1,135 · see citing works

CRISPR-Based Technologies for the Manipulation of Eukaryotic Genomes

Komor, A. C., Badran, A. H., & Liu, D. R. (2016) · Cell · doi:10.1016/j.cell.2016.10.044 · Cited by 1,011 · see citing works

Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS

Krönke, J., Fink, E. C., Hollenbach, P. W., MacBeth, K. J., Hurst, S. N., Udeshi, N. D., Chamberlain, P. P., Mani, D. R., Man, H. W., Gandhi, A. K., et al. (2015) · Nature · doi:10.1038/nature14610 · Cited by 863 · see citing works

Non-coding recurrent mutations in chronic lymphocytic leukaemia

Puente, X. S., Beà, S., Valdés‐Mas, R., Villamor, N., Gutiérrez‐Abril, J., Martín-Subero, J. I., Munar, M., Rubio-Pérez, C., Jares, P., Aymerich, M., et al. (2015) · Nature · doi:10.1038/nature14666 · Cited by 813 · see citing works

Delivery strategies of the CRISPR-Cas9 gene-editing system for therapeutic applications

Liu, C., Zhang, L., Liu, H., & Cheng, K. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.09.012 · Cited by 607 · see citing works

CRISPR/Cas9-based genome editing for disease modeling and therapy: challenges and opportunities for nonviral delivery

Wang, H.-X., Li, M., Lee, C. M., Chakraborty, S., Kim, H.-W., Bao, G., & Leong, K. W. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00799 · Cited by 560 · see citing works

Am I ready for CRISPR? A user's guide to genetic screens

Doench, J. G. (2018) · Nature Reviews Genetics · doi:10.1038/nrg.2017.97 · Cited by 452 · see citing works

CRISPR in cancer biology and therapy

Katti, A., Diaz, B. J., Caragine, C. M., Sanjana, N. E., & Dow, L. E. (2022) · Nature reviews. Cancer · doi:10.1038/s41568-022-00441-w · Cited by 440 · see citing works

CRISPR-Mediated Gene Editing to Assess the Roles of Tet2 and Dnmt3a in Clonal Hematopoiesis and Cardiovascular Disease

Sano, S., Oshima, K., Wang, Y., Katanasaka, Y., Sano, M., & Walsh, K. (2018) · Circulation Research · doi:10.1161/circresaha.118.313225 · Cited by 417 · see citing works

Non-viral delivery systems for CRISPR/Cas9-based genome editing: challenges and opportunities

Li, L., Hu, S., & Chen, X. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.04.031 · Cited by 415 · see citing works

Applications of the CRISPR-Cas9 system in cancer biology

Sánchez-Rivera, F. J., & Jacks, T. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3950 · Cited by 405 · see citing works

Multiplex CRISPR/Cas9-based genome engineering from a single lentiviral vector

Kabadi, A. M., Ousterout, D. G., Hilton, I. B., & Gersbach, C. A. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku749 · Cited by 371 · see citing works

Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies

Guièze, R., Liu, V. M., Rosebrock, D., Jourdain, A. A., Hernández-Sánchez, M., Martinez Zurita, A., Sun, J., Ten Hacken, E., Baranowski, K., Thompson, P. A., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.08.005 · Cited by 361 · see citing works

The Dynamic Landscape of Open Chromatin during Human Cortical Neurogenesis

de la Torre-Ubieta, L., Stein, J. L., Won, H., Opland, C. K., Liang, D., Lu, D., & Geschwind, D. H. (2018) · Cell · doi:10.1016/j.cell.2017.12.014 · Cited by 353 · see citing works

In vivo genome editing and organoid transplantation models of colorectal cancer and metastasis

Roper, J., Tammela, T., Cetinbas, N. M., Akkad, A., Roghanian, A., Rickelt, S., Almeqdadi, M., Wu, K., Oberli, M. A., Rivera, F. J. S., et al. (2017) · Nature Biotechnology · doi:10.1038/nbt.3836 · Cited by 345 · see citing works

Lipid accumulation induced by APOE4 impairs microglial surveillance of neuronal-network activity

Victor, M. B., Leary, N., Luna, X., Meharena, H. S., Scannail, A. N., Bozzelli, P. L., Samaan, G., Murdock, M. H., von Maydell, D., Effenberger, A. H., et al. (2022) · Cell Stem Cell · doi:10.1016/j.stem.2022.07.005 · Cited by 316 · see citing works

Refined sgRNA efficacy prediction improves large- and small-scale CRISPR–Cas9 applications

Labuhn, M., Adams, F. F., Ng, M. S. W., Knoess, S., Schambach, A., Charpentier, E., Schwarzer, A., Mateo, J. L., Klusmann, J., & Heckl, D. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx1268 · Cited by 289 · see citing works

CRISPR-Cas9: A Preclinical and Clinical Perspective for the Treatment of Human Diseases

Sharma, G., Sharma, A. R., Bhattacharya, M., Lee, S., & Chakraborty, C. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.09.028 · Cited by 295 · see citing works

Resident and Monocyte-Derived Macrophages in Cardiovascular Disease

Honold, L., & Nahrendorf, M. (2018) · Circulation Research · doi:10.1161/circresaha.117.311071 · Cited by 272 · see citing works

Core circadian clock genes regulate leukemia stem cells in AML

Puram, R. V., Kowalczyk, M. S., de Boer, C. G., Schneider, R. K., Miller, P. G., McConkey, M., Tothova, Z., Tejero, H., Heckl, D., Järås, M., et al. (2016) · Cell · doi:10.1016/j.cell.2016.03.015 · Cited by 274 · see citing works

Viral Delivery Systems for CRISPR

Xu, C. L., Ruan, M. Z. C., Mahajan, V. B., & Tsang, S. H. (2019) · Viruses · doi:10.3390/v11010028 · Cited by 277 · see citing works

Highly Efficient Genome Editing of Murine and Human Hematopoietic Progenitor Cells by CRISPR/Cas9

Gundry, M. C., Brunetti, L., Lin, A., Mayle, A. E., Kitano, A., Wagner, D., Hsu, J. I., Hoegenauer, K. A., Rooney, C. M., Goodell, M. A., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.09.092 · Cited by 265 · see citing works

Genomic deletion of malic enzyme 2 confers collateral lethality in pancreatic cancer

Dey, P., Baddour, J., Muller, F., Wu, C. C., Wang, H., Liao, W.-T., Lan, Z., Chen, A., Gutschner, T., Kang, Y., et al. (2017) · Nature · doi:10.1038/nature21052 · Cited by 264 · see citing works

Sublethal cytochrome c release generates drug-tolerant persister cells

Kalkavan, H., Chen, J., Crawford, J. C., Quarato, G., FITZGERALD, P. J., Tait, S. W. G., Goding, C. R., & Green, D. R. (2022) · Cell · doi:10.1016/j.cell.2022.07.025 · Cited by 267 · see citing works

Interferon-γ induces tumor resistance to anti-PD-1 immunotherapy by promoting YAP phase separation

Yu, M., Peng, Z., Qin, M., Liu, Y., Wang, J., Zhang, C., Lin, J., Dong, T., Wang, L., Li, S., et al. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.01.010 · Cited by 250 · see citing works

Artificial Virus Delivers CRISPR-Cas9 System for Genome Editing of Cells in Mice

Li, L., Song, L., Liu, X., Yang, X., Li, X., He, T., Wang, N., Yang, S., Yu, C., Yin, T., et al. (2017) · ACS Nano · doi:10.1021/acsnano.6b04261 · Cited by 244 · see citing works

PPM1D-truncating mutations confer resistance to chemotherapy and sensitivity to PPM1D inhibition in hematopoietic cells

Kahn, J. D., Miller, P. G., Silver, A. J., Sellar, R. S., Bhatt, S., Gibson, C., McConkey, M., Adams, D., Mar, B., Mertins, P., et al. (2018) · Blood · doi:10.1182/blood-2018-05-850339 · Cited by 225 · see citing works

Targeted DNA methylation in vivo using an engineered dCas9-MQ1 fusion protein

Lei, Y., Zhang, X., Su, J., Jeong, M., Gundry, M. C., Huang, Y.-H., Zhou, Y., Li, W., & Goodell, M. A. (2017) · Nature Communications · doi:10.1038/ncomms16026 · Cited by 218 · see citing works

Transgenic Mouse Models in Cancer Research

Tratar, U. L., Horvat, S., & Čemažar, M. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00268 · Cited by 216 · see citing works

Metabolic reprogramming induces resistance to anti-NOTCH1 therapies in T cell acute lymphoblastic leukemia

Herranz, D., Ambesi‐Impiombato, A., Sudderth, J., Sánchez-Martín, M., Belver, L., Tosello, V., Xu, L., Wendorff, A. A., Castillo-Martín, M., Haydu, J. E., et al. (2015) · Nature Medicine · doi:10.1038/nm.3955 · Cited by 210 · see citing works

Engineered materials for in vivo delivery of genome-editing machinery

Tong, S., Moyo, B., Lee, C. M., Leong, K. W., & Bao, G. (2019) · Nature Reviews Materials · doi:10.1038/s41578-019-0145-9 · Cited by 206 · see citing works

Challenges in CRISPR/CAS9 delivery: potential roles of nonviral vectors

Li, L., He, Z.-Y., Wei, X.-W., Gao, G.-P., & Wei, Y.-Q. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.069 · Cited by 202 · see citing works

PLA2G6 guards placental trophoblasts against ferroptotic injury

Beharier, O., Tyurin, V. A., Goff, J. P., Guerrero-Santoro, J., Kajiwara, K., Chu, T., Tyurina, Y. Y., St Croix, C. M., Wallace, C. T., Parry, S., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2009201117 · Cited by 198 · see citing works

Delivery and Specificity of CRISPR/Cas9 Genome Editing Technologies for Human Gene Therapy

Gori, J. L., Hsu, P. D., Maeder, M. L., Shen, S., Welstead, G. G., & Bumcrot, D. A. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.074 · Cited by 192 · see citing works

HOTTIP lncRNA Promotes Hematopoietic Stem Cell Self-Renewal Leading to AML-like Disease in Mice

Luo, H., Zhu, G., Xu, J., Lai, Q., Yan, B., Guo, Y., Fung, T. K., Zeisig, B. B., Cui, Y., Zha, J., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.10.011 · Cited by 192 · see citing works

CRISPR–Cas: a tool for cancer research and therapeutics

Yin, H., Xue, W., & Anderson, D. G. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0166-8 · Cited by 178 · see citing works

Multiplexed pancreatic genome engineering and cancer induction by transfection-based CRISPR/Cas9 delivery in mice

Maresch, R., Mueller, S., Veltkamp, C., Öllinger, R., Friedrich, M., Heid, I., Steiger, K., Weber, J., Engleitner, T., Barenboim, M., et al. (2016) · Nature Communications · doi:10.1038/ncomms10770 · Cited by 166 · see citing works

mTOR signaling in tumorigenesis

Xu, K. L., Liu, P., & Wei, W. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.10.007 · Cited by 167 · see citing works

Advances in CRISPR-Cas9 genome engineering: lessons learned from RNA interference

Barrangou, R., Birmingham, A., Wiemann, S., Beijersbergen, R. L., Hornung, V., & Smith, A. V. B. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv226 · Cited by 164 · see citing works

Patterns of CRISPR/Cas9 activity in plants, animals and microbes

Bortesi, L., Zhu, C., Zischewski, J., Pérez, L., Bassié, L., Nadi, R., Forni, G., Lade, S. B., Soto, E., Jin, X., et al. (2016) · Plant Biotechnology Journal · doi:10.1111/pbi.12634 · Cited by 159 · see citing works

CRISPR-Cas for genome editing: Classification, mechanism, designing and applications

Bhatia, S. K., ., P., & Yadav, S. K. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.124054 · Cited by 165 · see citing works

The SS18-SSX Oncoprotein Hijacks KDM2B-PRC1.1 to Drive Synovial Sarcoma

Banito, A., Li, X., Laporte, A. N., Roe, J., Sánchez-Vega, F., Huang, C., Dancsok, A. R., Hatzi, K., Chen, C.-C., Tschaharganeh, D. F., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.01.018 · Cited by 158 · see citing works

Unique and Shared Epigenetic Programs of the CREBBP and EP300 Acetyltransferases in Germinal Center B Cells Reveal Targetable Dependencies in Lymphoma

Meyer, S. N., Scuoppo, C., Vlasevska, S., Bal, É., Holmes, A. B., Holloman, M., Garcia‐Ibanez, L., Nataraj, S. E., Duval, R., Vantrimpont, T., et al. (2019) · Immunity · doi:10.1016/j.immuni.2019.08.006 · Cited by 153 · see citing works

Histone editing elucidates the functional roles of H3K27 methylation and acetylation in mammals

Sankar, A., Mohammad, F., Sundaramurthy, A. K., Wang, H., Lerdrup, M., Tatar, T., & Helin, K. (2022) · Nature Genetics · doi:10.1038/s41588-022-01091-2 · Cited by 152 · see citing works

CRISPR/Cas: Advances, Limitations, and Applications for Precision Cancer Research

Yang, Y., Xu, J., Ge, S., & Lai, L. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.649896 · Cited by 160 · see citing works

Lentiviral Vectors for Delivery of Gene-Editing Systems Based on CRISPR/Cas: Current State and Perspectives

Dong, W., & Kantor, B. (2021) · Viruses · doi:10.3390/v13071288 · Cited by 153 · see citing works

Lenalidomide promotes the development of TP53 -mutated therapy-related myeloid neoplasms

Sperling, A. S., Guerra, V. A., Kennedy, J. A., Yan, Y., Hsu, J. I., Wang, F., Nguyen, A. T., Miller, P. G., McConkey, M. E., Barrios, V. A. Q., et al. (2022) · Blood · doi:10.1182/blood.2021014956 · Cited by 153 · see citing works

A Rationally Designed Semiconducting Polymer Brush for NIR‐II Imaging‐Guided Light‐Triggered Remote Control of CRISPR/Cas9 Genome Editing

Li, L., Yáng, Z., Zhu, S., He, L., Fan, W., Tang, W., Zou, J., Shen, Z., Zhang, M., Tang, L., et al. (2019) · Advanced Materials · doi:10.1002/adma.201901187 · Cited by 146 · see citing works

HOTTIP-dependent R-loop formation regulates CTCF boundary activity and TAD integrity in leukemia

Luo, H., Zhu, G., Eshelman, M. A., Fung, T. K., Lai, Q., Wang, F., Zeisig, B. B., Lesperance, J., Ma, X., Shi, C., et al. (2022) · Molecular Cell · doi:10.1016/j.molcel.2022.01.014 · Cited by 145 · see citing works

Recent advances and applications of CRISPR-Cas9 in cancer immunotherapy

Liu, Z., Shi, M., Ren, Y., Xu, H., Weng, S., Ning, W., Ge, X., Liu, L., Guo, C., Duo, M., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01738-6 · Cited by 146 · see citing works

SETD2 alterations impair DNA damage recognition and lead to resistance to chemotherapy in leukemia

Mar, B. G., Chu, S. H., Kahn, J. D., Krivtsov, A. V., Koche, R. P., Castellano, C. A., Kotlier, J. L., Zon, R. L., McConkey, M. E., Chabon, J. R., et al. (2017) · Blood · doi:10.1182/blood-2017-03-775569 · Cited by 139 · see citing works

3D Genome of macaque fetal brain reveals evolutionary innovations during primate corticogenesis

Luo, X., Liu, Y., Dang, D., Hu, T., Hou, Y., Meng, X., Zhang, F., Li, T., Wang, C., Li, M., et al. (2021) · Cell · doi:10.1016/j.cell.2021.01.001 · Cited by 137 · see citing works

Small molecule promotes β-catenin citrullination and inhibits Wnt signaling in cancer

Qu, Y., Olsen, J. R., Xing, Y., Cheng, P. F., Levesque, M. P., Brokstad, K. A., Hoffman, P. S., Oyan, A. M., Zhang, W., Kalland, K., et al. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2510 · Cited by 141 · see citing works

Nanoparticles for nucleic acid delivery: Applications in cancer immunotherapy

Mukalel, A. J., Riley, R., Zhang, R., & Mitchell, M. J. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.04.040 · Cited by 140 · see citing works

Efficient delivery of nuclease proteins for genome editing in human stem cells and primary cells

Liu, J., Gaj, T., Yang, Y., Wang, N., Shui, S., Kim, S., Kanchiswamy, C. N., Kim, J., & Barbas, C. F. (2015) · Nature Protocols · doi:10.1038/nprot.2015.117 · Cited by 127 · see citing works

CRISPR/Cas9 gene-editing: Research technologies, clinical applications and ethical considerations

Memi, F., Ntokou, A., & Papangeli, I. (2018) · Seminars in Perinatology · doi:10.1053/j.semperi.2018.09.003 · Cited by 130 · see citing works

Multiplexed genetic engineering of human hematopoietic stem and progenitor cells using CRISPR/Cas9 and AAV6

Bak, R. O., Dever, D. P., Reinisch, A., Cruz Hernandez, D., Majeti, R., & Porteus, M. H. (2017) · eLife · doi:10.7554/elife.27873 · Cited by 122 · see citing works

Reshaping Tumor Immune Microenvironment through Acidity-Responsive Nanoparticles Featured with CRISPR/Cas9-Mediated Programmed Death-Ligand 1 Attenuation and Chemotherapeutics-Induced Immunogenic Cell Death

Tu, K., Deng, H., Kong, L., Wang, Y., Yang, T., Hu, Q., Hu, M. Y., Yang, C., & Zhang, Z. (2020) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.9b23084 · Cited by 122 · see citing works

A Non-catalytic Function of SETD1A Regulates Cyclin K and the DNA Damage Response

Hoshii, T., Cifani, P., Feng, Z., Huang, C., Koche, R. P., Chen, C.-W. D., Delaney, C. D., Lowe, S. W., Kentsis, A., & Armstrong, S. A. (2018) · Cell · doi:10.1016/j.cell.2018.01.032 · Cited by 120 · see citing works

A CRISPR-Cas9 delivery system for in vivo screening of genes in the immune system

LaFleur, M. W., Nguyen, T. H., Coxe, M. A., Yates, K. B., Trombley, J. D., Weiss, S. A., Brown, F. D., Gillis, J. E., Coxe, D. J., Doench, J. G., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09656-2 · Cited by 117 · see citing works

Promoting antibody-dependent cellular phagocytosis for effective macrophage-based cancer immunotherapy

Cao, X., Chen, J., Li, B., Dang, J., Zhang, W., Zhong, X., Wang, C., Raoof, M., Sun, Z., Yu, J., et al. (2022) · Science Advances · doi:10.1126/sciadv.abl9171 · Cited by 117 · see citing works

Advances and perspectives on the use of CRISPR/Cas9 systems in plant genomics research

Liu, D., Hu, R., Palla, K. J., Tuskan, G. A., & Yang, X. (2016) · Current Opinion in Plant Biology · doi:10.1016/j.pbi.2016.01.007 · Cited by 115 · see citing works

A somatic role for the histone methyltransferase Setdb1 in endogenous retrovirus silencing

Kato, M., Takemoto, K., & Shinkai, Y. (2018) · Nature Communications · doi:10.1038/s41467-018-04132-9 · Cited by 94 · see citing works

Precision cancer mouse models through genome editing with CRISPR-Cas9

Mou, H., Kennedy, Z., Anderson, D. G., Yin, H., & Xue, W. (2015) · Genome Medicine · doi:10.1186/s13073-015-0178-7 · Cited by 113 · see citing works

Fumarate hydratase inactivation in hereditary leiomyomatosis and renal cell cancer is synthetic lethal with ferroptosis induction

Kerins, M. J., Milligan, J., Wohlschlegel, J. A., & Ooi, A. (2018) · Cancer Science · doi:10.1111/cas.13701 · Cited by 110 · see citing works

The Ftx Noncoding Locus Controls X Chromosome Inactivation Independently of Its RNA Products

Furlan, G., Hernandez, N. G., Huret, C., Galupa, R., van Bemmel, J. G., Romito, A., Heard, É., Morey, C., & Rougeulle, C. (2018) · Molecular Cell · doi:10.1016/j.molcel.2018.03.024 · Cited by 106 · see citing works

A glance at genome editing with CRISPR–Cas9 technology

Barman, A., Deb, B., & Chakraborty, S. (2019) · Current Genetics · doi:10.1007/s00294-019-01040-3 · Cited by 105 · see citing works

The SPPL3-Defined Glycosphingolipid Repertoire Orchestrates HLA Class I-Mediated Immune Responses

Jongsma, M. L. M., de Waard, A. A., Raaben, M., Zhang, T., Cabukusta, B., Platzer, R., Blomen, V. A., Xagara, A., Verkerk, T., Bliss, S., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.11.003 · Cited by 108 · see citing works

Clonal hematopoiesis, somatic mosaicism, and age-associated disease

Evans, M. A., & Walsh, K. (2022) · Physiological Reviews · doi:10.1152/physrev.00004.2022 · Cited by 105 · see citing works

Modeling Disease In Vivo With CRISPR/Cas9

Dow, L. E. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2015.07.006 · Cited by 105 · see citing works

Mapping a functional cancer genome atlas of tumor suppressors in mouse liver using AAV-CRISPR–mediated direct in vivo screening

Wang, G., Chow, R. D.-W., Ye, L., Guzman, C. D., Dai, X., Dong, M. B., Zhang, F., Sharp, P. A., Platt, R. J., & Chen, S. (2018) · Science Advances · doi:10.1126/sciadv.aao5508 · Cited by 100 · see citing works

Resources for the design of CRISPR gene editing experiments

Graham, D. B., & Root, D. E. (2015) · Genome biology · doi:10.1186/s13059-015-0823-x · Cited by 102 · see citing works

CRISPR technologies for stem cell engineering and regenerative medicine

Hsu, M., Chang, Y., Truong, V. A., Lai, P., Nguyen, T. K. N., & Hu, Y. (2019) · Biotechnology Advances · doi:10.1016/j.biotechadv.2019.107447 · Cited by 105 · see citing works

Carrier strategies boost the application of CRISPR/Cas system in gene therapy

Xu, Z., Wang, Q., Zhong, H., Jiang, Y., Shi, X., Yuan, B., Yu, N., Zhang, S., Yuan, X., Guo, S., et al. (2022) · Exploration · doi:10.1002/exp.20210081 · Cited by 104 · see citing works

Overview of the Use of Murine Models in Leukemia and Lymphoma Research

Kohnken, R. A., Porcu, P., & Mishra, A. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00022 · Cited by 102 · see citing works

Multiplex CRISPR/Cas9-Based Genome Editing in Human Hematopoietic Stem Cells Models Clonal Hematopoiesis and Myeloid Neoplasia

Tóthová, Z., Krill-Burger, J. M., Popova, K. D., Landers, C. C., Sievers, Q. L., Yudovich, D., Belizaire, R., Aster, J. C., Morgan, E. A., Tsherniak, A., et al. (2017) · Cell stem cell · doi:10.1016/j.stem.2017.07.015 · Cited by 96 · see citing works

Jak2V617F and Dnmt3a loss cooperate to induce myelofibrosis through activated enhancer-driven inflammation

Jacquelin, S., Straube, J., Cooper, L., Vu, T., Song, A., Bywater, M., Baxter, E., Heidecker, M., Wackrow, B., Porter, A., et al. (2018) · Blood · doi:10.1182/blood-2018-04-846220 · Cited by 99 · see citing works

CRISPR/Cas System and Factors Affecting Its Precision and Efficiency

Javaid, N., & Choi, S. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.761709 · Cited by 98 · see citing works

Genetic screens and functional genomics using CRISPR /Cas9 technology

Hartenian, E., & Doench, J. G. (2015) · FEBS Journal · doi:10.1111/febs.13248 · Cited by 97 · see citing works

CRISPR/Cas9 – An evolving biological tool kit for cancer biology and oncology

Tian, X., Gu, T., Patel, S., Bode, A. M., Lee, M., & Dong, Z. (2019) · npj Precision Oncology · doi:10.1038/s41698-019-0080-7 · Cited by 98 · see citing works

Vitamin B6 Addiction in Acute Myeloid Leukemia

Chen, C.-C., Li, B., Millman, S. E., Chen, C., Li, X., Morris, J. P., Mayle, A., Ho, Y.-J., Loizou, E., Liu, H., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2019.12.002 · Cited by 95 · see citing works

Viral vectors and extracellular vesicles: innate delivery systems utilized in CRISPR/Cas-mediated cancer therapy

Ahmadi, S. E., Soleymani, M., Shahriyary, F., Amirzargar, M. R., Mahya, O., Fattahi, D., & Safa, M. (2023) · Cancer Gene Therapy · doi:10.1038/s41417-023-00597-z · Cited by 95 · see citing works

Tissue Engineering and Regenerative Medicine 2015: A Year in Review

Wobma, H., & Vunjak‐Novakovic, G. (2015) · Tissue Engineering Part B Reviews · doi:10.1089/ten.teb.2015.0535 · Cited by 92 · see citing works

CRISPR-DT: designing gRNAs for the CRISPR-Cpf1 system with improved target efficiency and specificity

Zhu, H., & Liang, C. (2019) · Bioinformatics · doi:10.1093/bioinformatics/bty1061 · Cited by 86 · see citing works

Site-specific methylation of 18S ribosomal RNA by SNORD42A is required for acute myeloid leukemia cell proliferation

Pauli, C., Liu, Y., Rohde, C., Cui, C., Fijałkowska, D., Gerloff, D., Walter, C., Krijgsveld, J., Dugas, M., Edemir, B., et al. (2020) · Blood · doi:10.1182/blood.2019004121 · Cited by 91 · see citing works

Chronic myeloid leukemia stem cells: targeting therapeutic implications

Mojtahedi, H., Yazdanpanah, N., & Rezaei, N. (2021) · Stem Cell Research & Therapy · doi:10.1186/s13287-021-02659-1 · Cited by 91 · see citing works

CRISPR/Cas9: Transcending the Reality of Genome Editing

Chira, S., Gulei, D., Hajitou, A., Zimța, A., Cordelier, P., & Berindan‐Neagoe, I. (2017) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2017.04.001 · Cited by 88 · see citing works

Aberrant Activation of a Gastrointestinal Transcriptional Circuit in Prostate Cancer Mediates Castration Resistance

Shukla, S., Cyrta, J., Murphy, D. A., Walczak, E. G., Ran, L., Agrawal, P. K., Xie, Y., Chen, Y., Wang, S., Zhan, Y., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.10.008 · Cited by 83 · see citing works

In vivo blunt-end cloning through CRISPR/Cas9-facilitated non-homologous end-joining

Geisinger, J. M., Turan, S., Hernandez, S., Spector, L. P., & Calos, M. P. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1542 · Cited by 83 · see citing works

ATF7IP regulates SETDB1 nuclear localization and increases its ubiquitination

Tsusaka, T., Shimura, C., & Shinkai, Y. (2019) · EMBO Reports · doi:10.15252/embr.201948297 · Cited by 83 · see citing works

CRISPR genome engineering and viral gene delivery: A case of mutual attraction

Schmidt, F., & Grimm, D. (2015) · Biotechnology Journal · doi:10.1002/biot.201400529 · Cited by 83 · see citing works

Controlling organoid symmetry breaking uncovers an excitable system underlying human axial elongation

Anand, G. M., Megale, H. C., Murphy, S. H., Weis, T., Lin, Z., He, Y., Wang, X., Jia Liu, B., & Ramanathan, S. (2023) · Cell · doi:10.1016/j.cell.2022.12.043 · Cited by 81 · see citing works

Risk associated with off-target plant genome editing and methods for its limitation

Zhao, H., & Wolt, J. D. (2017) · Emerging Topics in Life Sciences · doi:10.1042/etls20170037 · Cited by 78 · see citing works

The prolactin receptor long isoform regulates nociceptor sensitization and opioid-induced hyperalgesia selectively in females

Chen, Y., Moutal, A., Navratilova, E., Kopruszinski, C. M., Yue, X., Ikegami, M., Chow, M., Kanazawa, I., Bellampalli, S. S., Xie, J. Y., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aay7550 · Cited by 78 · see citing works

Current approaches in CRISPR-Cas9 mediated gene editing for biomedical and therapeutic applications

Bhattacharjee, G., Gohil, N., Khambhati, K., Mani, I., Maurya, R., Karapurkar, J. K., Gohil, J., Chu, D., Vu‐Thi, H., Alzahrani, K. J., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.02.005 · Cited by 78 · see citing works

Application of CRISPR/Cas9 gene editing technique in the study of cancer treatment

Jiang, C., Meng, L., Yang, B., & Luo, X. (2019) · Clinical Genetics · doi:10.1111/cge.13589 · Cited by 79 · see citing works

Efficient Gene Disruption in Cultured Primary Human Endothelial Cells by CRISPR/Cas9

Abrahimi, P., Chang, W., Kluger, M. S., Qyang, Y., Tellides, G., Saltzman, W. M., & Pober, J. S. (2015) · Circulation Research · doi:10.1161/circresaha.117.306290 · Cited by 77 · see citing works

Clonal expansion and myeloid leukemia progression modeled by multiplex gene editing of murine hematopoietic progenitor cells

Shi, X.-G., Kitano, A., Jiang, Y., Luu, V., Hoegenauer, K. A., & Nakada, D. (2018) · Experimental Hematology · doi:10.1016/j.exphem.2018.04.009 · Cited by 18 · see citing works

Transgenic expression of enhanced AsCas12a in mice enables In Vivo multiplex genetic editing and development of diverse novel models of myeloid neoplasms

Loke, C. T., Brown, J., McConkey, M. E., Miller, A., Hergott, C., Shin, W., McGee, A. V., Doench, J. G., & Ebert, B. L. (2025) · Blood · doi:10.1182/blood-2025-3227

Generation of Models of Human Hematologic Malignancies Using CRISPR Genome Engineering

Tóthová, Z., Krill-Burger, J. M., Popova, K. D., Sievers, Q. L., Yudovich, D., Belizaire, R., Aster, J. C., Morgan, E. A., Tsherniak, A., & Ebert, B. L. (2016) · Blood · doi:10.1182/blood.v128.22.741.741 · Cited by 3 · see citing works

Mouse Models of Myeloid MalignanciesPreprint

Basheer, F., & Vassiliou, G. S. (2020) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a035535 · Cited by 6 · see citing works

Mouse models of myeloid cancers created with clustered, regularly interspaced short palindromic repeats (CRISPR)-mediated genome editing

(2014) · Science-Business eXchange · doi:10.1038/scibx.2014.907